PDL BioPharma (PDLI) Reports Q2 EPS of $0.39

PDL BioPharma (NASDAQ: PDLI) reported Q2 EPS of $0.39, versus $0.03 reported last year. Revenue for the quarter came in at $143.8 million, versus $21 million reported last year.

For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79